Ultragenyx Pharmaceutical
RARE
312 hedge funds and large institutions have $3.68B invested in Ultragenyx Pharmaceutical in 2024 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 111 increasing their positions, 109 reducing their positions, and 42 closing their positions.
31% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 42
4% more funds holding
Funds holding: 300 → 312 (+12)
2% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 109
0.49% more ownership
Funds ownership: 94.27% → 94.76% (+0.49%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
17% less call options, than puts
Call options by funds: $31.5M | Put options by funds: $37.9M
24% less capital invested
Capital invested by funds: $4.82B → $3.68B (-$1.14B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$37.2M |
| 2 |
BlackRock
New York
|
+$35.1M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$32.4M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
+$32.4M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$26.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$84.7M |
| 2 |
Alkeon Capital Management
New York
|
-$65.7M |
| 3 |
Sands Capital Management
Arlington,
Virginia
|
-$40.7M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$37.9M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$27.6M |
RARE Hedge Fund Activity: Q4 2024 in Review
312 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2024, worth a combined $3.68B — down 24% from $4.82B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new RARE positions and 42 closed out — a net gain of 13 holders — while 111 added to existing stakes and 109 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $37.2M. The largest seller was Wellington Management Group, cutting an estimated $84.7M.
- 312 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2024, up from 300 in Q3 2024.
- Funds reported $3.68B of Ultragenyx Pharmaceutical stock for Q4 2024, down 24% quarter-over-quarter.
- 55 funds opened new Ultragenyx Pharmaceutical positions in Q4 2024 and 42 closed out, a net change of +13 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q4 2024 was Vestal Point Capital, an estimated $37.2M added.
- The largest Ultragenyx Pharmaceutical seller in Q4 2024 was Wellington Management Group, an estimated $84.7M sold.
Based on aggregated 13F filings for Q4 2024.